Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Da Silva, Hannah E ^a   Teterina, Anastasia ^b   Comelli, Elena M ^c   Taibi, Amel ^c   Arendt, Bianca M ^b   Fischer, Sandra E ^b   Lou, Wendy ^c   Allard, Johane P ^b,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; BODY MASS; COMPLICATION; CROSS-SECTIONAL STUDY; DYSBIOSIS; FECES; FEMALE; HUMAN; INSULIN RESISTANCE; INTESTINE FLORA; MALE; MICROBIOLOGY; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; YOUNG ADULT;

ADULT; AGED; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DYSBIOSIS; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85041023949     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-19753-9     Document Type: Article

References (59)

1. Younossi, Z. M. et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 9, 524-530.e521; quiz e560, https://doi.org/10.1016/j.cgh.2011.03.020 (2011).
2. Vanni, E. et al. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 42, 320-330, https://doi.org/10.1016/j. dld.2010.01.016 (2010).
3. Rotman, Y., Koh, C., Zmuda, J. M., Kleiner, D. E. &Liang, T. J. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 52, 894-903, https://doi.org/10.1002/hep.23759 (2010).
4. Farrell, G. C. &Larter, C. Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43, S99-S112, https://doi. org/10.1002/hep.20973 (2006).
5. Alam, S., Mustafa, G., Alam, M. &Ahmad, N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World journal of gastrointestinal pathophysiology 7, 211-217, https://doi.org/10.4291/wjgp.v7.i2.211 (2016).
6. Marchesini, G., Petta, S. &Dalle Grave, R. Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice. Hepatology 63, 2032-2043, https://doi.org/10.1002/hep.28392 (2016).
7. Wieland, A., Frank, D. N., Harnke, B. &Bambha, K. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol Ther 42, 1051-1063, https://doi.org/10.1111/apt.13376 (2015).
8. Chassaing, B., Etienne-Mesmin, L. &Gewirtz, A. T. Microbiota-liver axis in hepatic disease. Hepatology 59, 328-339, https://doi. org/10.1002/hep.26494 (2014).
9. Mouzaki, M. et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 58, 120-127, https://doi. org/10.1002/hep.26319 (2013).
10. Spencer, M. D. et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 140, 976-986, https://doi.org/10.1053/j.gastro.2010.11.049 (2011).
11. Zhu, L. et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57, 601-609, https://doi.org/10.1002/hep.26093 (2013).
12. Raman, M. et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 11(868-875), e861-863, https://doi.org/10.1016/j.cgh.2013.02.015 (2013).
13. Wong, V. W. et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis-A longitudinal study. PLoS One 8, e62885, https://doi.org/10.1371/journal.pone.0062885 (2013).
14. Jiang, W. et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Scientific reports 5, 8096, https://doi.org/10.1038/srep08096 (2015).
15. Boursier, J. et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63, 764-775, https://doi.org/10.1002/hep.28356 (2016).
16. Del Chierico, F. et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology 65, 451-464, https://doi.org/10.1002/hep.28572 (2017).
17. Leung, C., Rivera, L., Furness, J. B. &Angus, P. W. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol 13, 412-425, https://doi.org/10.1038/nrgastro.2016.85 (2016).
18. Arendt, B. M. et al. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. Hepatology 61, 1565-1578, https://doi.org/10.1002/hep.27695 (2015).
19. Da Silva, H. E. et al. A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls. Journal of the Academy of Nutrition and Dietetics 114, 1181-1194, https://doi.org/10.1016/j. jand.2014.01.009 (2014).
20. Pan, X. R. et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20, 537-544 (1997).
21. Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A. &Bacon, B. R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94, 2467-2474 (1999).
22. Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321, https://doi.org/10.1002/hep.20701 (2005).
23. Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419 (1985).
24. Psychogios, N. et al. The human serum metabolome. PLoS One 6, e16957, https://doi.org/10.1371/journal.pone.0016957 (2011).
25. Caporaso, J. G. et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. Isme j 6, 1621-1624, https://doi.org/10.1038/ismej.2012.8 (2012).
26. Gloor, G. B. et al. Microbiome Profiling by Illumina Sequencing of Combinatorial Sequence-Tagged PCR Products. PLoS One 5, e15406, https://doi.org/10.1371/journal.pone.0015406 (2010).
27. Masella, A. P., Bartram, A. K., Truszkowski, J. M., Brown, D. G. &Neufeld, J. D. PANDAseq: paired-end assembler for illumina sequences. BMC Bioinformatics 13, 31, https://doi.org/10.1186/1471-2105-13-31 (2012).
28. Edgar, R. C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26, 2460-2461, https://doi.org/10.1093/ bioinformatics/btq461 (2010).
29. Quast, C. et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res 41, D590-596, https://doi.org/10.1093/nar/gks1219 (2013).
30. Schloss, P. D. et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl. Environ. Microbiol. 75, 7537-7541, https://doi.org/10.1128/aem.01541-09 (2009).
31. Le Gall, G. et al. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. J Proteome Res 10, 4208-4218, https://doi.org/10.1021/pr2003598 (2011).
32. Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nature methods 7, 335-336, https:// doi.org/10.1038/nmeth.f.303 (2010).
33. Lozupone, C. A. &Knight, R. Species divergence and the measurement of microbial diversity. FEMS Microbiol. Rev. 32, 557-578, https://doi.org/10.1111/j.1574-6976.2008.00111.x (2008).
34. Bullard, J. H., Purdom, E., Hansen, K. D. &Dudoit, S. Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments. BMC Bioinformatics 11, 94, https://doi.org/10.1186/1471-2105-11-94 (2010).
35. Paulson, J. N., Stine, O. C., Bravo, H. C. &Pop, M. Differential abundance analysis for microbial marker-gene surveys. Nature methods 10, 1200-1202, https://doi.org/10.1038/nmeth.2658 (2013).
36. White, J. R., Nagarajan, N. &Pop, M. Statistical methods for detecting differentially abundant features in clinical metagenomic samples. PLoS Comput Biol 5, e1000352, https://doi.org/10.1371/journal.pcbi.1000352 (2009).
37. Benjamini, Y. &Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57, 289-300 (1995).
38. Macfarlane, S. &Macfarlane, G. T. Regulation of short-chain fatty acid production. Proc Nutr Soc 62, 67-72, https://doi.org/10.1079/ pns2002207 (2003).
39. LaBrecque, D. R. et al. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol 48, 467-473, https://doi.org/10.1097/mcg.0000000000000116 (2014).
40. Lakshminarayanan, B., Stanton, C., O'Toole, P. W. &Ross, R. P. Compositional dynamics of the human intestinal microbiota with aging: implications for health. J Nutr Health Aging 18, 773-786, https://doi.org/10.1007/s12603-014-0513-5 (2014).
41. Yatsunenko, T. et al. Human gut microbiome viewed across age and geography. Nature 486, 222-227, https://doi.org/10.1038/ nature11053 (2012).
42. Odamaki, T. et al. Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study. BMC microbiology 16, 90, https://doi.org/10.1186/s12866-016-0708-5 (2016).
43. Buford, T. W. (Dis) Trust your gut: the gut microbiome in age-related inflammation, health, and disease. Microbiome 5, 80, https:// doi.org/10.1186/s40168-017-0296-0 (2017).
44. Table 105-0501 and Catalogue no. 82-221-X. (Statistics Canada, 2016).
45. Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 105, 16731-16736, https://doi.org/10.1073/pnas.0804812105 (2008).
46. Haro, C. et al. The gut microbial community in metabolic syndrome patients is modified by diet. J Nutr Biochem 27, 27-31, https:// doi.org/10.1016/j.jnutbio.2015.08.011 (2016).
47. Shaw, K. A. et al. Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease. 8, 75, https://doi.org/10.1186/s13073-016-0331-y (2016).
48. Scheppach, W. &Weiler, F. The butyrate story: old wine in new bottles? Curr Opin Clin Nutr Metab Care 7, 563-567 (2004).
49. Sartor, R. B. Key questions to guide a better understanding of host-commensal microbiota interactions in intestinal inflammation. Mucosal immunology 4, 127-132, https://doi.org/10.1038/mi.2010.87 (2011).
50. Crost, E. H. et al. Utilisation of mucin glycans by the human gut symbiont Ruminococcus gnavus is strain-dependent. PLoS One 8, e76341, https://doi.org/10.1371/journal.pone.0076341 (2013).
51. Hynonen, U. et al. Isolation and whole genome sequencing of a Ruminococcus-like bacterium, associated with irritable bowel syndrome. Anaerobe 39, 60-67, https://doi.org/10.1016/j.anaerobe.2016.03.001 (2016).
52. Schwiertz, A. et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 18, 190-195, https://doi. org/10.1038/oby.2009.167.
53. Jumpertz, R. et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 94, 58-65, https://doi.org/10.3945/ajcn.110.010132 (2011).
54. Mushref, M. A. &Srinivasan, S. Effect of high fat-diet and obesity on gastrointestinal motility. Annals of translational medicine 1, 14, https://doi.org/10.3978/j.issn.2305-5839.2012.11.01 (2013).
55. Vogt, J. A. &Wolever, T. M. Fecal acetate is inversely related to acetate absorption from the human rectum and distal colon. J Nutr 133, 3145-3148 (2003)
56. 2-Hydroxybutyric acid.
57. Doelle, H. W. Bacterial Metabolism. Second edn, 416-419 (Academic Press, Inc., 1975).
58. Ferrannini, E. et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes 62, 1730-1737, https://doi.org/10.2337/db12-0707 (2013).
59. Su, D. et al. Vitamin D Signaling through Induction of Paneth Cell Defensins Maintains Gut Microbiota and Improves Metabolic Disorders and Hepatic Steatosis in Animal Models. Frontiers in physiology 7, 498, https://doi.org/10.3389/fphys.2016.00498 (2016).